Poor metabolization of n-hexane in Parkinson's disease

Journal of Neurology

Volumn 250, Issue 5, 2003, Pages 556-560

  Canesi, M ^a   Perbellini, L ^b   Maestri, L ^c   Silvani, A ^a   Zecca, L ^d   Bet, L ^e   Pezzoli, Gianni ^a  

^a PARKINSON INSTITUTE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c IRCCS   (Italy)

^d INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

2,5 hexanedione; Aging; Hydrocarbons; Metabolism; n hexane; Parkinson's disease

Indexed keywords

2,5 DIMETHYLPYRROLE; ACETONYLACETONE; HEXANE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGING; ARTICLE; BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; URINARY EXCRETION;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; FEMALE; HEXANES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0038579522     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-1035-y     Document Type: Article

References (33)

1. Abou-Donia & Gupta. Axonopathy and involvement of cytoskeletal proteins in chemically induced neuropathies. In: Principles of neurotoxicology. Ed Marcel Dekker, Inc
2. Brugnone F, Perbellini L, Langston JW, Widner H, Goetw CG, et al. (1994) Blood interface in environmental and occupational exposure to industrial chemical pollutants. G Ital Med Lav 16:11-17
3. Chan DK, Mellick GD, Buchanan DD, et al. (2002) Lack of association between CIP1A1 polymorphism and Parkinson disease in a Chinese population. J Neoral Trasm 109:35-39
4. Checkoway H, Nelson LM (1999) Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 10:327-336
5. Crosbie SJ, Blain P, Williams FM (1997) Metabolism of n-hexane by rat liver and extrahepatic tissues and the effect of cytochrome P-450 inducers. Hum Exp Toxicol 16:131-137
6. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P-450 3A4 inhibition. Clin Pharmacokinet 38:41-57
7. Dupont I, Bodenez P, Berthou F, Simon B, Bardou LG, Lucas D (2000) Cytochrome P-450 2E1 activity and oxidative stress in alcoholic patients. Alcohol Alcohol 35:98-103
8. Fedtke N, Bolt HM (1986) Detection of 2,5-hexanedione in the urine of persons not exposed to n-hexane. Int Arch Occup Environ Health 57:143-148
9. Habib MP, Clements NC, Garewal HS (1995) Cigarette Smoking and Ethane Exhalation in Humans. Am J Respir Crit Care Med 151:1368-1372
10. Hageman G, van der Hock J, van Hout M, et al. (1999) Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J Neurol 246:198-206
11. Kessler W, Heilmaier H, Kreuzer P, et al. (1990) Spectrophotometric determination of pyrrole-like substances in urine of rat and man: an assay for the evaluation of 2,5-hexanedione formed from n-hexane. Arch Toxicol 64:242-246
12. Koller WC (1992) When does Parkinson's disease begin? Neurology 42:27-31
13. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y (1988) Lewy bodies are ubiquinated. A light and electron microscopic immunochemical study. Acta Neuropathol (Berl) 75:345-353
14. Langston JW, Widner H, Goetz CG, et al. (1992) Core assessment program for Intracerebral transplantations (CAPIT). Mov Disord 7:2-13
15. Maestri L, Ghittori S, Imbriani M, et al. (1994) Determination of 2,5-hexanedione by high-performance liquid chromatography after derivatization with dansylhydrazine. J Chromatogr B Biomed Appl 657:111-117
16. Martin ER, Scott WK, Nance MA, et al. (2001) Association of single nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 286:2245-2250
17. Perbellini L, Faccini GB, Pasini F, et al. (1988) Environmental and occupational exposure to benzene by analysis of breath and blood. Br J Ind Med 45:345-352
18. Perbellini L, Marhuenda Amoros AD, Cardona Llorens LA, et al. (1990) An improved method of analysing 2,5-hexanedione in urine. Br J Ind Med 47:421-424
19. Perbellini L, Pezzoli G, Brugnone F, Canesi M (1993) Biochemical and physiological aspects of 2,5-hexanedione: endogenous or exogenous product? Int Arch Occup Environ Health 65:49-52
20. Pezzoli G, Canesi M, Antonini A, et al. (2000) Hydrocarbon exposure and Parkinson's Disease. Neurology 55:667-673
21. Rango M, Righini A, Farabola M, Bettinelli A, Scarlato G (2000) Parkinson's Disease. Toxic exposure and basal ganglia: a proton magnetic resonance spectroscopy study. Neurology 54 (Suppl 3):A445
22. Riedl AG, Watts PM, Jenner PM, et al. (1998) P450 Enzymes and Parkinson's Disease: The story so far. Mov Disord 13:212-220
23. Scott WK, Nance MA, Watts RL, et al. (2001) Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286:2239-2244
24. Sherer TB, Betarbet R, Greenamyre JT (2001) Pathogenesis of Parkinson's disease. Curr Opin Investig Drugs 2:657-662
25. Tan EK, Khajavi M, Thornby JL, Nagamitsu S, Janokovic J, Ashizawa T (2000) Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55:533-538
26. Tanner CM, Ottman R, Goldman SM, et al(1999) Parkinson disease in twins: an etiologic study. JAMA 281:341-346
27. Tanner CM, Goldman SM, Aston DA, et al. (2002) Smoking and Parkinson disease in Queens. Neurology 58:581-588
28. Tetrud JW, Langston JW, Irwin I, Snow B (1994) Parkinsonism caused by petroleum waste ingestion. Neurology 44:1051-1054
29. Tuckwell DS, Laszlo L, Mayer RJ (1992) 2,5-hexanedione-induced intermediate filament aggregates contain ubiquitin-protein conjugate immunoreactivity and resemble Rosenthal fibers. Neuropathol Appl
30. Uitti RJ, Snow BJ, Shinotoh H, et al. (1994) Parkinsonism induced by solvent abuse. Ann Neurol 35:616-619
31. Vaz AD, Coon MJ (1987) Hydrocarbon formation in the reduction cleavage of hydroperoxides by cytochrome P-450. Proc Natl Acad Sci USA 84:1172-1176
32. Wang J, Liu Z, Chan P (2000) Lack of association between cytochrome P450 2E1 gene polymorphisms and Parkinson's Disease in a Chinese Population Mov Disord 15:1267-1269
33. WHO working group (1991) n-Hexane. Environmental Health Criteria: 122